SEMA7A Antibody

What is SEMA7A and what are its primary biological functions?

SEMA7A (Semaphorin 7A), also known as CD108 and SEMAL, is a member of the semaphorin family and represents the only membrane-associated glycosylphosphatidylinositol (GPI)-linked semaphorin. It has diverse biological roles:

• Neuronal Development: Plays a crucial role in neuronal axon outgrowth and guidance during development

• Immune Regulation: Modulates cytokine-induced memory-like responses in NK cells and controls T cell responses via the α1β1 integrin receptor

• Inflammation: Essential for the resolution of severe inflammation by orchestrating macrophage polarization toward the M2 phenotype

• Blood System: Carries the John Milton Hagen (JMH) human blood group antigen on red blood cells

SEMA7A has two isoforms with molecular weights of 73 and 75 kDa, respectively, with the calculated molecular weight being 75 kDa (666 amino acids) and observed molecular weight typically between 75-80 kDa in experimental conditions .

SEMA7A expression has been documented in multiple tissues and cell types:

• Neuronal Tissues: Robust expression in brain regions including neural circuits in the lateral line

• Immune System: Expression on NK cells (upregulated upon cytokine stimulation), T cells, and macrophages

• Blood Cells: Present on red blood cells as the JMH blood group antigen

• Other Tissues: Detected in placenta, testis, ovary, and spleen

In the immune system, SEMA7A expression is dynamically regulated; for example, it is substantially upregulated on NK cells stimulated with cytokines, specifically marking activated NK cells .

How should researchers optimize Western blot protocols for SEMA7A detection?

For optimal Western blot detection of SEMA7A:

• Sample Preparation:

  • Use tissues with known expression (placenta, brain tissue) as positive controls

  • For human samples, red blood cells and placenta tissue have been validated

  • For mouse samples, brain, testis, and ovary tissues show reliable detection

• Antibody Dilution:

  • Polyclonal antibodies (e.g., 18070-1-AP): Use 1:1000-1:4000

  • Monoclonal antibodies (e.g., 67397-1-Ig): Use 1:2000-1:6000

  • For R&D Systems antibody (AF1835): 0.25 μg/mL has been validated

• Molecular Weight Expectations:

  • Look for bands between 75-80 kDa

  • Note that in some systems (e.g., Simple Western), SEMA7A may appear at approximately 109 kDa

• Reduction Conditions:

  • Reducing conditions are recommended for most validated protocols

What strategies can be used to validate SEMA7A antibody specificity?

Validating SEMA7A antibody specificity is crucial for experimental reliability:

• Genetic Controls:

  • Use tissues from Sema7A^(-/-) knockout mice as negative controls, which should show no immunoreactivity

  • The search results indicate that no SEMA7A protein was detected in the ME (median eminence) of Sema7A mutant mice

• Cross-Species Validation:

  • If claiming cross-reactivity, confirm detection in multiple species (human, mouse)

  • Note that some antibodies are species-specific; for example, 67397-1-Ig is validated for human but not mouse samples

• Multiple Antibody Approach:

  • Use different antibodies targeting distinct epitopes of SEMA7A

  • Compare results from both monoclonal and polyclonal antibodies

• Immunoprecipitation-Western Blot:

  • Perform IP followed by WB to confirm antibody specificity

  • For example, one study used this approach to detect SEMA7A-Itgb1 interactions

What are the recommended methods for co-immunoprecipitation studies involving SEMA7A?

For successful co-immunoprecipitation of SEMA7A and its binding partners:

• Protocol Example for SEMA7A-Itgb1 Co-IP :

  • Incubate cells (e.g., ADSCs) with 10 μg/mL Sema7A for 3 hours

  • Lyse cells with appropriate lysis buffer (e.g., Beyotime Biotechnology P0013)

  • Preclear lysates with protein G

  • Immunoprecipitate with Sema7A antibody (18070-1-AP, Proteintech) or IgG control

  • Detect co-immunoprecipitated proteins by Western blot using appropriate antibodies (e.g., Itgb1 antibody)

• Antibody Quantities:

  • For IP, use 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

  • Validate in human placenta tissue, which has shown positive IP results

• Controls:

  • Always include an isotype-matched IgG control

  • Include input sample (pre-IP lysate) in Western blot analysis

  • Consider including reverse co-IP (using antibody against the binding partner)

How can researchers distinguish between different SEMA7A variants in experimental systems?

SEMA7A displays molecular diversity, including polymorphisms like R461C with different functional properties . To distinguish between variants:

• RT-PCR for Transcript Variants :

  • SEMA7A gene expresses two transcript variants:

    • Variant 1 (sema7a-GPI anchored, NM_001328508.1)

    • Variant 2 (sema7a secreted, NM_001114885.2)

  • Use specific primers to distinguish these variants:

    • For variant 1: sema7aF= 5′-GGTTTTTCTGAGGCCATTCC-3′, sema7aR1= 5′-GGCACTCGTGACAAATGCTA-3′

    • For variant 2: sema7aF= 5′-GGTTTTTCTGAGGCCATTCC-3′, sema7aR2= 5′-TGTGGAGAAAGTCACAAAGCA-3′

• Variant-Specific Antibodies:

  • Consider generating or obtaining antibodies that specifically recognize the R461C variant

  • In research by Kang et al. (referenced in source 9), recombinant wild-type Sema7A (Sema7A_wt) and R461C variant (Sema7A_R461C) were produced in human embryonic kidney cells to study their differential effects

• Functional Assays:

  • T-cell proliferation assays can distinguish variants (Sema7A_R461C induces T-cell activation while Sema7A_wt has minimal effect)

  • Measure granzyme B transcript levels, which are differentially affected by variants (up to 220-fold upregulation with Sema7A_R461C)

How do SEMA7A antibodies perform in studying immune cell populations and activation states?

SEMA7A antibodies are valuable tools for studying immune activation, particularly:

• NK Cell Studies :

  • SEMA7A expression marks activated NK cells with strong cytokine-producing capacity

  • Flow cytometry using SEMA7A antibodies can identify:

    • ~60% of SEMA7A+ NK cells co-express CD25 after IL-12+IL-18 stimulation

    • ~90% co-express IL-18Rα

    • SEMA7A+ CD56bright NK cells often co-express CD27, which defines a subpopulation with enhanced IFN-γ secretion capacity

• T Cell Activation Analysis :

  • SEMA7A antibodies can help identify T cell populations responding to different Sema7A variants

  • Particularly useful for studying antigen-independent T cell activation induced by Sema7A_R461C

  • Can be combined with antibody blocking studies to demonstrate β1 integrin dependence of SEMA7A-mediated T cell activation

• Macrophage Polarization :

  • SEMA7A antibodies can be used to study macrophage phenotypic changes:

    • Detect reduction in M1 markers (STAT-1, CD40, CD80)

    • Monitor increases in M2 markers (Arg1, CD163, CD206)

    • Evaluate expression of G-protein-coupled receptors ALX/FPR2 and GPR32

What approach should be used to investigate SEMA7A distribution and localization in tissue samples?

For optimal SEMA7A localization in tissues:

• Immunofluorescence Protocol Example (from zebrafish studies) :

  • Fix specimens overnight at 4°C in 4% formaldehyde in PBS with 1% Tween-20

  • Wash with 1% PBST (4 times, 15 min each)

  • Block with 2% normal donkey serum, 0.5% Tween-20, and 1% BSA for 2 hours

  • Incubate with primary antibodies overnight at 4°C:

    • Goat anti-Sema7A (1:200; AF1835, R&D Systems)

    • Additional antibodies for co-labeling (e.g., anti-myosin VI, anti-GM130)

  • Wash with 0.1% PBST (4 times, 15 min each)

  • Apply Alexa Fluor-conjugated secondary antibodies (1:200) overnight

  • Final washing and mounting steps

• Measurement Techniques :

  • Quantify Sema7A fluorescence intensities in different cellular compartments

  • Use line profile tools (e.g., in ImageJ) to measure intensity distribution across cellular domains

  • Scale measurements appropriately (0-1 arbitrary units) for consistent comparisons

• Considerations for Neuronal Tissues :

  • When examining brain regions like the hypothalamus, use co-labeling with markers like vimentin to identify tanycytes

  • Include BSLI (Bandeiraea simplicifolia lectin I) to label endothelial cells

  • Consider using GnRH antibodies for neuroendocrine studies

How should researchers address variable molecular weights observed for SEMA7A in different experiments?

SEMA7A's observed molecular weight can vary in experimental conditions:

• Expected Variation Range:

  • Calculated molecular weight: 75 kDa (666 amino acids)

  • Typically observed: 75-80 kDa range in most Western blot applications

  • Some detection methods (e.g., Simple Western) may show bands at approximately 109 kDa

• Potential Sources of Variation:

  • Post-translational modifications: SEMA7A is a glycoprotein, and differential glycosylation can alter apparent molecular weight

  • Isoforms: Two reported isoforms with molecular weights of 73 and 75 kDa

  • Detection method: Different separation systems may affect observed molecular weight (e.g., 12-230 kDa separation system used in Simple Western)

  • Sample preparation: Reduction conditions influence migration pattern

• Validation Strategy:

  • Always include positive control samples with known SEMA7A expression (e.g., human placenta, mouse brain)

  • Consider running lysates from various tissues (brain, testis, ovary) to compare migration patterns

  • When possible, compare antibodies from different sources targeting distinct epitopes

What are the critical storage conditions for maintaining SEMA7A antibody performance?

Proper storage is essential for antibody stability and performance:

For maximum stability:

• Avoid repeated freeze-thaw cycles

• Consider creating working aliquots for experiments

• For antibodies in PBS only, extra care should be taken to prevent microbial contamination

How can researchers resolve conflicting data from different SEMA7A detection methods?

When facing conflicting results across different detection methods:

• Cross-Validation Strategy:

  • Compare results from at least two distinct antibody clones

  • Validate findings using complementary techniques (e.g., if WB shows unexpected results, confirm with IP or IF)

  • Include genetic controls when possible (e.g., Sema7A^(-/-) samples)

• Method-Specific Considerations:

  • Western Blot: Ensure proper blocking and antibody titration; test multiple antibody dilutions (1:1000-1:6000 range)

  • Immunofluorescence: Different fixation methods may yield varying results; compare fixation protocols

  • Flow Cytometry: Consider activation state of cells, as SEMA7A expression is dynamically regulated in immune cells

• Biological Variables:

  • SEMA7A expression is highly dynamic and context-dependent:

    • In NK cells, expression increases significantly after cytokine stimulation

    • Expression patterns differ between CD56bright and CD56dim NK cell subsets

    • During inflammation, expression changes over time (correlating with resolution phases)

How can SEMA7A antibodies be utilized to study inflammation resolution mechanisms?

Recent research has revealed SEMA7A's crucial role in inflammation resolution:

• Macrophage Polarization Studies :

  • Use SEMA7A antibodies to track expression during inflammation progression and resolution

  • Monitor polarization shift from M1 to M2 phenotype using flow cytometry or imaging

  • Correlate SEMA7A expression with resolution markers:

    • Reduced proinflammatory cytokines

    • Enhanced IL-10 production

    • Specialized pro-resolving lipid mediators (SPMs)

• Metabolic Reprogramming Analysis :

  • SEMA7A orchestrates macrophage metabolic remodeling critical for resolution

  • Compare wild-type and Sema7A^(-/-) macrophages to examine:

    • Fatty acid oxidation

    • Oxidative phosphorylation

    • Glycolysis and pentose phosphate pathway activity

    • TCA cycle intermediates (succinate, fumarate, citrate)

• Therapeutic Potential Evaluation :

  • Use recombinant Sema7A or its variant Sema7A SL4cd to:

    • Assess resolution interval shortening

    • Measure impact on survival in sepsis models

    • Evaluate tissue protection mechanisms

What approaches can be used to investigate SEMA7A's role in neuronal development and function?

For neuronal studies involving SEMA7A:

• Neural Circuit Development :

  • Use immunofluorescence with SEMA7A antibodies to:

    • Track progressive basal accumulation of Sema7A in hair cells

    • Examine association of sensory axon terminals with hair cells

    • Monitor Sema7A distribution along the apicobasal axis

• Intensity Measurement Techniques :

  • Quantify Sema7A and td-Tomato+ sensory arbor fluorescence intensities:

    • Determine mean gray level within each cell or structure

    • Use line profile tools to measure intensity distribution across membranes

    • Scale measurements appropriately (0-1 arbitrary units)

• Neuroendocrine Studies :

  • Examine SEMA7A's role in the adult hypothalamus:

    • Co-labeling with vimentin to identify tanycytes

    • Study GnRH neuronal plasticity

    • Investigate SEMA7A's interaction with PlexinC1 in mediating neuroglial plasticity

How should researchers design experiments to study SEMA7A variants and their differential effects?

To effectively study SEMA7A variants like R461C:

• Recombinant Protein Production :

  • Generate both wild-type (Sema7A_wt) and variant (e.g., Sema7A_R461C) proteins:

    • Express in human embryonic kidney cells

    • Purify and validate protein identity and purity

• Functional Comparison Assays :

  • T-cell activation:

    • Measure proliferation with and without antigen stimulation

    • Assess phenotypic alterations (flow cytometry)

    • Quantify granzyme B transcript levels (up to 220-fold difference between variants)

    • Analyze secretion of proinflammatory cytokines

• Receptor Dependency Studies :

  • Perform antibody blocking studies to determine receptor involvement:

    • Use β1 integrin blocking antibodies to assess dependency

    • Compare with PlexinC1 blocking to distinguish pathway contributions

    • Quantify differential effects on downstream signaling pathways (mTOR, AKT2)

• In vivo Models :

  • Evaluate variant effects in disease models:

    • Acute inflammation models (e.g., peritonitis)

    • Sepsis models (e.g., CLP - cecal ligation and puncture)

    • Monitor survival rates, resolution intervals, and tissue protection